Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease

Relationship Between Systemic Inflammation, Thyroid Autoimmunity, and Neuroretinal Structures in Graves Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07480720

Enrollment

100

Registered

2026-03-18

Start date

2026-03-01

Completion date

2026-05-01

Last updated

2026-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves Disease, Graves Ophthalmopathy

Keywords

Graves disease, Thyroid autoimmunity, Systemic inflammation, Optical coherence tomography, Retinal nerve fiber layer, Graves ophthalmopathy

Brief summary

This retrospective observational study aims to evaluate the relationship between systemic inflammatory parameters, thyroid autoimmunity markers, and neuroretinal structures in patients with Graves disease. Medical records of patients diagnosed with Graves disease and healthy control subjects evaluated at Elazığ Fethi Sekin City Hospital between August 2018 and January 2026 will be reviewed. Optical coherence tomography (OCT) measurements, including macular thickness and peripapillary retinal nerve fiber layer (RNFL) thickness, will be analyzed. Laboratory parameters such as complete blood count-derived inflammatory indices, C-reactive protein, thyroid function tests, and thyroid autoantibodies will also be recorded. The study will compare neuroretinal parameters between healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy, and will investigate potential associations between systemic inflammation, thyroid autoimmunity, and neuroretinal structural changes.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Age ≥ 18 years Diagnosis of Graves' disease (for the patient group) No known thyroid disease in healthy control participants Availability of optical coherence tomography (OCT) measurements and laboratory data Time interval between OCT examination and blood sampling ≤ 10 days

Exclusion criteria

* Presence of glaucoma, optic neuropathy, or retinal vascular diseases Macular diseases, uveitis, or severe refractive error (high myopia \>6 diopters) Diabetic retinopathy History of previous intraocular surgery History of active infection, malignancy, or systemic inflammatory disease Poor-quality OCT measurements (segmentation errors or low signal strength)

Design outcomes

Primary

Measure	Time frame	Description
Peripapillary Retinal Nerve Fiber Layer Thickness	Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026	Evaluation and comparison of peripapillary retinal nerve fiber layer thickness values in different quadrants among study groups.
Macular Thickness Measured by Optical Coherence Tomography	Retrospective evaluation of OCT measurements obtained between August 2018 and January 2026	Comparison of macular thickness measurements among healthy controls, Graves disease patients without ophthalmopathy, and Graves disease patients with ophthalmopathy.

Countries

Turkey (Türkiye)

Contacts

CONTACTSİNEM KESER, MD

kesersinem@hotmail.com+905070646384

Outcome results